The debate noted BBB penetration challenges but didn't resolve which senolytics reach effective brain levels without off-target toxicity. This pharmacokinetic gap is essential for translating peripheral senolytic success to neurodegeneration. Source: Debate session sess_SDA-2026-04-04-gap-senescent-clearance-neuro_20260416-151700 (Analysis: SDA-2026-04-04-gap-senescent-clearance-neuro)
Landscape Summary: Which senolytic compounds achieve therapeutic CNS concentrations while maintaining selectivity for senescent cells? is a 0.82 priority gap in pharmacology. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Which senolytic compounds achieve therapeutic CNS concentrations while maintaining selectivity for senescent cells? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: